Clinical trial
Study to Investigate the Safety, Tolerability, Absorption, Distribution…
NCT00396422 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00396422 |
|---|---|
| Title | Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis |
| Official title | A Phase IIa Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multi-Center, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RWJ-445380 Administered to Patients With Plaque Psoriasis |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Small Plaque Psoriasis |
| Intervention type | Drug |
| Interventions | RWJ-445380 |
| Enrollment | 60 |
| Start date | Sep 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Nov 7, 2006 |
| Last update posted | Feb 18, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: